Title |
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting
|
---|---|
Published in |
PLOS ONE, March 2013
|
DOI | 10.1371/journal.pone.0058643 |
Pubmed ID | |
Authors |
Anders Svenningsson, Eva Falk, Elisabeth G. Celius, Siegrid Fuchs, Karen Schreiber, Sara Berkö, Jennifer Sun, Iris-Katharina Penner, for the TYNERGY trial investigators |
Abstract |
Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue. In this one-armed clinical trial including 195 MS patients, natalizumab was prescribed in a real-life setting, and a validated questionnaire, the Fatigue Scale for Motor and Cognitive functions (FSMC), was used both before and after 12 months of treatment to evaluate a possible change in the fatigue experienced by the patients. In the treated cohort all measured variables, that is, fatigue score, quality of life, sleepiness, depression, cognition, and disability progression were improved from baseline (all p values<0.0001). Walking speed as measured by the six-minute walk-test also increased at month 12 (p = 0.0016). All patients were aware of the nature of the treatment agent, and of the study outcomes. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Unknown | 162 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 21 | 13% |
Researcher | 20 | 12% |
Student > Ph. D. Student | 19 | 12% |
Student > Master | 18 | 11% |
Other | 9 | 6% |
Other | 28 | 17% |
Unknown | 48 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 37 | 23% |
Psychology | 21 | 13% |
Nursing and Health Professions | 11 | 7% |
Neuroscience | 7 | 4% |
Social Sciences | 5 | 3% |
Other | 24 | 15% |
Unknown | 58 | 36% |